Mong Cho

Mong Cho

Auto-generated profile, based on publicly available information

Mong Cho

Pusan National University Yangsan Hospital

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2004 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HCHyung Jun Chu
Hyung Jun Chu
JHJeong Heo
Jeong Heo
SSSoo Boon Seo
Soo Boon Seo
GKGwang Ha Kim
Gwang Ha Kim
DKDae Hwan Kang
Dae Hwan Kang
UYUng Suk Yang
Ung Suk Yang
Chu HJ, et al. J Korean Med Sci. 2004 Feb;19(1):83-86. https://doi.org/10.3346/jkms.2004.19.1.83

26 February 2014 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
CCCheol Woong Choi
Cheol Woong Choi
GSGyung Mo Son
Gyung Mo Son
DKDae-Hwan Kang
Dae-Hwan Kang
YHYong Mi Hong
Yong Mi Hong
SKSu Jin Kim
Su Jin Kim
JHJoung Boom Hong
Joung Boom Hong

1 January 2004 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JHJeong Heo
Jeong Heo
MCMong Cho
Mong Cho
HKHyung Hoi Kim
Hyung Hoi Kim
YSYoung Min Shin
Young Min Shin
HJHyun Jung Jang
Hyun Jung Jang
UYUng Suk Yang
Ung Suk Yang
Heo J, et al. J Korean Med Sci. 2004 Aug;19(4):541-546. https://doi.org/10.3346/jkms.2004.19.4.541

30 June 2007 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
Gwang Ha KimGwang Ha Kim
Gwang Ha Kim
GSGeun Am Song
Geun Am Song
TKTae-Oh Kim
Tae-Oh Kim
HJHong Jae Jo
Hong Jae Jo
AKASAN MEDICAL CENTER Kim
ASAN MEDICAL CENTER Kim
DKDae-Hwan Kang
Dae-Hwan Kang

17 April 2012 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
HWHyun Young Woo
Hyun Young Woo
Jeong HeoJeong Heo
Jeong Heo
KYKi Tae Yoon
Ki Tae Yoon
Gwang Ha KimGwang Ha Kim
Gwang Ha Kim
DKDae-Hwan Kang
Dae-Hwan Kang
MCMong Cho
Mong Cho
Sorafenib has been shown to improve survival of patients with advanced hepatocellular carcinoma (HCC). However, its tolerance in clinical practice has not been well evaluated, and whether sorafenib should be continued in cases of tumor progression or intolerance has not been established. The authors retrospectively assessed sorafenib tolerability, and evaluated the clinical course in patients who showed progression during sorafenib treatment. Between March 2008 and July 2010, 80 patients with advanced HCC were treated with sorafenib. With a median of 78.5 days of treatment, 15% discontinued sorafenib due to adverse events. The duration was significantly longer in patients with Child-Pugh class A liver function (233 ± 240 days) than in those with Child-Pugh class B (100 ± 136 days; p = 0.006). The overall progression rate was 53% (43/80), with a median time to progression of 105 days (95% confidence interval, 59-150 days). After progression, 14 patients received conservative care only (group 1), 14 continued sorafenib monotherapy (group 2), 6 changed to treatment without sorafenib (group 3) and 9 underwent additional treatment with concomitant sorafenib (group 4). Survival after progression was significantly better in groups 2, 3 and 4 than in group 1 (p = 0.001). Sorafenib was tolerable for most patients in clinical practice and may be continued in patients who show progression during sorafenib therapy. However, it was less well tolerated in patients with Child-Pugh class B liver function and should be used with caution in these patients.

1 January 2021 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
JLJae Seung Lee
Jae Seung Lee
YCYoung Eun Chon
Young Eun Chon
BKBeom Kyung Kim
Beom Kyung Kim
JPJun Yong Park
Jun Yong Park
Do Young KimDo Young Kim
Do Young Kim
TGThe Korean TACE Study Group
The Korean TACE Study Group
Lee JS, et al. Yonsei Med J. 2021 Jan;62(1):12-20. https://doi.org/10.3349/ymj.2021.62.1.12